K211372 is an FDA 510(k) clearance for the Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) Mobile Application.... Classified as Computerized Behavioral Therapy Device For Treating Symptoms (product code QMY), Class II - Special Controls.
Submitted by Mahana Therapeutics, Inc. (San Francisco, US). The FDA issued a Cleared decision on June 2, 2021 after a review of 29 days - a notably fast clearance cycle.
This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.5960 - the FDA gastroenterology and urology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.
Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.
View all Mahana Therapeutics, Inc. devices